Connect Biopharma reports positive Phase 2 asthma, COPD data for rademikibart
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)
4 stories
The company plans FDA meetings in December 2026 for asthma and the first quarter of 2027 for COPD to discuss Phase 3 development.
SEC filing (4)
Traws Pharma said ratutrelvir showed no viral rebound and fewer side effects than PAXLOVID in a 92-patient COVID-19 study, and will seek an FDA path for PAXLOVID-ineligible patients.
SEC filing
The biotech, formerly Onconova Therapeutics, registered a committed equity line under a Rule 506(b) exemption with one investor to date.
SEC filing
The October 26, 2026 filing registers resale shares tied to the $50 million Roth Principal Investments purchase agreement, as Traws stock closed at $0.34.
SEC filing (2)